Search Results

Your search for Javier Cort��s, MD,Javier Cort��s, MD matches 2 pages

Showing 1 - 2

By Matthew Stenger / Monday, January 11, 2016 9:30 AM

No Benefit Shown With Afatinib in HER2-Positive Breast Cancer With Progressive Brain Metastases

In the phase II LUX-Breast 3 trial reported in The Lancet Oncology, Cortés et al found that afatinib (Gilotrif) alone or combined with vinorelbine did not increase patient benefit vs investigator choice of treatment in patients with HER2-positive breast cancer and progressive brain...

breast cancer

By Caroline Helwick / Monday, September 29, 2014 11:38 AM

ESMO 2014: CLEOPATRA Study Shows ‘Unprecedented’ Survival With Dual HER2 Blockade in Metastatic Breast Cancer

In the final overall survival analysis of the phase III CLEOPATRA trial, patients with HER2-positive metastatic breast cancer patients lived 15.7 months longer if they received pertuzumab (Perjeta) in addition to trastuzumab (Herceptin) and docetaxel, investigators reported at the ESMO 2014...

Jan

Today In Oncology

Search Results

Your search for Javier Cort��s, MD,Javier Cort��s, MD matches 2 pages

No Benefit Shown With Afatinib in HER2-Positive Breast Cancer With Progressive Brain Metastases

ESMO 2014: CLEOPATRA Study Shows ‘Unprecedented’ Survival With Dual HER2 Blockade in Metastatic Breast Cancer

New Study Shows Increased Cancer Mortality Among Patients With Type 2 Diabetes in England

Trends in Use of Next-Generation Sequencing in U.S. Patients According to Genetic Ancestry

Risk of Subsequent Gastrointestinal Tract Malignancies After Blood or Marrow Transplantation

Addition of Pazopanib to Concurrent Radiotherapy and Paclitaxel in Anaplastic Thyroid Cancer

New Analysis Sheds Light on Potential Link Between Ovulation and Ovarian Cancer